| アブストラクト | RATIONALE: While meta-analyses of clinical trials found that lurasidone and partial dopamine agonists (brexpiprazole and aripiprazole) were the antipsychotics less likely to cause QTc prolongation, and sertindole, amisulpride, and ziprasidone were the most frequently associated with this adverse drug reaction; no real-world studies have investigated this risk between the different antipsychotics. OBJECTIVES AND METHODS: Using data recorded from 1967 to 2019 in VigiBase(R), the World Health Organization's Global Individual Case Safety Reports database, we performed disproportionality analysis to investigate the risk of reporting QT prolongation between 20 antipsychotics. RESULTS: Sertindole had the highest risk of reporting QT prolongation, followed by ziprasidone and amisulpride. Lurasidone was associated with the lowest risk. First-generation antipsychotics were associated with a greater QT prolongation reporting risk (ROR, 1.21; 95%CI, 1.10-1.33) than second-generation antipsychotics. A positive correlation was found between the risk of reporting QT prolongation and affinity for hERG channel (R(2) = 0.14, slope = Pearson coefficient = 0.41, p value = 0.1945). CONCLUSIONS: This large study in a real-world setting suggests that sertindole and ziprasidone were the antipsychotics drugs associated with the highest risk of QT prolongation reporting. Our results suggest that lurasidone is less associated with QT interval prolongation reports. Our study also suggests that antipsychotics with the higher hERG affinity are more associated with to QT prolongations reports. |
|---|
| 投稿者 | Bordet, Constance; Garcia, Philippe; Salvo, Francesco; Touafchia, Anthony; Galinier, Michel; Sommet, Agnes; Montastruc, Francois |
|---|
| 組織名 | Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and;Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital, 37;Allees Jules Guesde, 31000, Toulouse, France.;Clinical Investigation Centre INSERM 1436, Team PEPSS (Pharmacologie En;Population Cohortes Et Biobanques), Faculty of Medicine, University Hospital,;Toulouse, France.;Univ. Bordeaux, INSERM, U1219, F-33000, Bordeaux, BPH, France.;Pharmacology Unit, CHU de Bordeaux, Centre of Pharmacovigilance, 33000, Bordeaux,;France.;Department of Cardiology, Faculty of Medicine, Toulouse University Hospital,;Allees Jules Guesde, 31000, Toulouse, France. francois.montastruc@univ-tlse3.fr. |
|---|
